Multiple sclerosis: Fingolimod failure in progressive MS INFORMS future trials
暂无分享,去创建一个
[1] Ludwig Kappos,et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial , 2016, The Lancet.
[2] D. Ontaneda,et al. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives , 2015, The Lancet Neurology.
[3] B. Trapp,et al. Pathological mechanisms in progressive multiple sclerosis , 2015, The Lancet Neurology.
[4] Ludwig Kappos,et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial , 2014, The Lancet Neurology.
[5] Jeffrey A. Cohen,et al. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis , 2011, Annals of neurology.
[6] Ludwig Kappos,et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.
[7] P. Calabresi,et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial , 2009, Annals of neurology.
[8] P. Narayana,et al. Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trial , 2007, Annals of neurology.
[9] Ludwig Kappos,et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. , 2006, The New England journal of medicine.
[10] D. Arnold,et al. Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study , 2015 .